Christopher Lieu is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 395 publications with 10,849 citations (h-index 45); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 20 Jun 2013.
Clinical trials
- Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Sponsor: University of Colorado, Denver
- Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Sponsor: Criterium, Inc.
- Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20255 payments
- PFIZER INC.Program year20241 payment
- PFIZER INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
68.8%Antidiarrheal microorganisms20%Creon100%Part D<11 patientsOpioid Agonist14.4%Loperamide100%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
20%Kinase inhibitor10.4%Everolimus100%Part D<11 patientsPoly(ADP-Ribose) Polymerase Inhibitor9.6%Lynparza100%Part D<11 patientsNervous system
11.2%Phenothiazine11.2%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2015–2020 per NIH RePORTER. The latest:
- Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
University of Colorado Denver
FY2020$548,097R01CA229259 - Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
University of Colorado Denver
FY2019$541,043R01CA229259 - Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
University of Colorado Denver
FY2018$247,340R01CA229259
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bryan Haugen, MD
University of Colorado Cancer Center
Wells Messersmith, MD
University of Colorado Cancer Center
Thomas Flaig, MD
University of Colorado Cancer Center
Ritu Salani, MD
University of Colorado Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”